# Reduced immunotherapy doses during Lebanon's drug shortage and outcomes in stage IV lung cancer

Source: https://onco.cc/key-papers/paper-hodroj-nsclc-immunotherapy-shortage-lebanon-jcogo-2026/  
OnCo record `paper-hodroj-nsclc-immunotherapy-shortage-lebanon-jcogo-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In a study of stage IV non-small cell lung cancer treated before and during Lebanon's immunotherapy shortage, 56% of patients given immunotherapy received reduced doses; progression-free survival did not differ significantly from before the crisis, in a study not designed to prove equivalence.

## Summary

Published as "Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon". The authors, at the Naef K. Basile Cancer Institute of the American University of Beirut Medical Center and other centres, compared patients treated from January 2019 to December 2020 with those treated from October 2021 to December 2022, when the economic collapse caused shortages and interruptions of immunotherapy.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: JCO Global Oncology
- Year: 2026
- DOI: 10.1200/go-26-00203
- Authors: Hodroj MH, Numan H, El-Halabi L, et al.
- Findings: 158 eligible patients were included (73 before the crisis, 85 during it).; Among immunotherapy recipients 44.0% received full-dose therapy, 41.4% received 50% to 99% of the standard dose and 14.7% received less than 50%.; Median progression-free survival was 6.33, 12.86 and 10.23 months in those groups; the difference was not statistically significant (P = .132).
- What it means: Records how Lebanese oncologists stretched scarce immunotherapy during the shortage; the authors caution that the study cannot show reduced doses work as well.
- Caveats: Retrospective and not powered to establish equivalence.; Short-term progression-free survival only.

## Sources

- JCO Glob Oncol 2026: https://doi.org/10.1200/go-26-00203
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42485593/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- institutions: [American University of Beirut Medical Center / Naef K. Basile Cancer Institute](https://onco.cc/institutions/aubmc-basile-cancer-institute/)
- people: [Arafat Tfayli](https://onco.cc/people/arafat-tfayli/)

---
JSON: https://onco.cc/api/v1/entities/paper-hodroj-nsclc-immunotherapy-shortage-lebanon-jcogo-2026.json